Pembrolizumab increases long-term survival in patients with advanced NSCLC

Expanding clinical trial eligibility criteria: Risks and solutions

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer

ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer

ASCO 2019 and vision for cancer control

Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers: Results from a phase II basket trial

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastatic breast cancer

Guiding treatment decisions through the use of molecular profiling in breast cancer

Managing metastatic breast cancer and beyond using PARP inhibitors

Updates in metastatic and early-stage breast cancer

PARP inhibitors in metastatic breast cancer: Where are we now?

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus chemotherapy in early breast cancer